Global  

Gilead Sciences

American pharmaceutical company

Gilead Sciences    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

0
shares
ShareTweetSavePostSend
 

Gilead's remdesivir gets conditional EU clearance [Video]

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients. As Fred Katayama reports, that makes it the region's first..

Credit: Reuters Studio     Duration: 00:59Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now..

Credit: Wochit News     Duration: 00:35Published
AstraZeneca shares down after report it approached Gilead [Video]

AstraZeneca shares down after report it approached Gilead

Shares in Britain's AstraZeneca opened lower on Monday after a report it had approached U.S. rival Gilead Sciences about a possible merger. Ciara Lee reports

Credit: Reuters Studio     Duration: 01:09Published
Stocks rise on recovery hopes [Video]

Stocks rise on recovery hopes

U.S. stocks posted gains Monday as signs of U.S. economic recovery helped offset jitters over increasingly violent social unrest amid an ongoing pandemic and rising U.S.-China tensions. Fred Katayama..

Credit: Reuters Studio     Duration: 01:22Published
EU close to fast-tracking COVID-19 treatment drug [Video]

EU close to fast-tracking COVID-19 treatment drug

The head of the European Union's medicines agency, Guido Rasi, has said an initial authorization for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming..

Credit: Reuters Studio     Duration: 01:40Published
WHO sees 'potentially positive data' in treating coronavirus [Video]

WHO sees 'potentially positive data' in treating coronavirus

The Geneva-based WHO is leading a global initiative to develop safe and effective vaccines, tests and drugs to prevent, diagnose and treat COVID-19. The respiratory illness has infected 4.19 million..

Credit: Reuters Studio     Duration: 01:12Published

You Might Like


Trump ‘Undermining’ Global Fight Against Covid By Hoarding New Drug, Minister Warns

trump ‘undermining’ global fight against covid by hoarding new drug, minister warns
Donald Trump risks “undermining” global collaboration on Covid-19 by buying up the world’s supplies of a drug treatment for the virus, the British government has warned. Business minister Nadhim..
WorldNews - Published

Coronavirus: US buys nearly all of Gilead's Covid-19 drug remdesivir

The US will acquire almost all the next three months' production of the drug from Gilead.
BBC News - Published

Virus-fighting drug's cost announced

virus-fighting drug's cost announced
Gilead Sciences said it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir, or about $2,340 for a typical five-day course of..
WorldNews - Published

Remdesivir, the First Coronavirus Drug, Gets a Price Tag

Federal health officials and Gilead Sciences have settled on priority distribution to Americans — and nonnegotiable pricing.
NYTimes.com - Published

Coronavirus updates: More states close bars, slow reopening plans; Gilead Sciences sets price for remdesivir treatments

California Gov. Gavin Newsom ordered some bars to close. Arizona and Washington slow down reopenings. Latest coronavirus news.
USATODAY.com - Published

FDA warns against co-administration of remdesivir with CQ or HCQ for COVID-19 patients

fda warns against co-administration of remdesivir with cq or hcq for covid-19 patients
Hyderabad, June 16 () The US Food and Drug Administration (USFDA) warned healthcare providers against co-administration of Gilead Sciences remdesivir, which received emergency use authorization for..
WorldNews - Published

FDA warns against combination of malaria drug and Gilead's remdesivir

The U.S. Food and Drug Administration on Monday issued a warning to healthcare providers against administering malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences'..
Reuters India - Published Also reported by •Reuters

India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivir

Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show..
Reuters India - Published

India's Zydus Cadila signs pact with Gilead to make remdesivir

Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in..
Reuters India - Published

Singapore approves remdesivir drug for emergency COVID-19 treatment

Singapore on Wednesday approved the use of Gilead Sciences Inc's antiviral drug remdesivir for the treatment of severely ill patients with COVID-19 infection.
Reuters - Published

Gilead's remdesivir prevents lung damage in COVID-19 study on monkeys

Gilead Sciences Inc's antiviral drug remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus, according to a study published in the journal Nature on Tuesday.
Reuters India - Published

AstraZeneca contacted Gilead over potential megamerger: Bloomberg News

Britain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies, Bloomberg News reported on Sunday, citing people familiar with..
Reuters - Published

Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analyst

Gilead Sciences Inc's potential COVID-19 treatment, remdesivir, could bring in more than $7 billion in annual sales by 2022, spurred by governments stockpiling the drug to guard against future..
Reuters - Published

India approves Gilead's remdesivir to treat severe COVID-19 cases

India's government has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients.
Reuters India - Published Also reported by •WorldNews

Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions

Gilead Sciences Inc is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after..
Reuters - Published Also reported by •Reuters India

India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir

India's drug regulator has granted US pharma giant Gilead Sciences marketing authorisation for its anti-viral drug remdesivir for "restricted emergency use" on hospitalised Covid-19 patients in view of..
IndiaTimes - Published

Gilead's remdesivir shows modest improvement in moderate COVID-19 patients

Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received..
Reuters - Published

Gilead says drug helped moderately ill coronavirus patients

gilead says drug helped moderately ill coronavirus patients
A California biotech company says its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalized patients with COVID-19. Gilead Sciences gave few details on..
WorldNews - Published

European, South Korean authorities vie for COVID-19 antiviral remdesivir

European and South Korean authorities are vying for Gilead Sciences' potential COVID-19 treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is..
Reuters - Published

South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge

South Korean health authorities said on Friday they would request imports of Gilead Sciences Inc's anti-viral drug remdesivir to treat COVID-19, as new outbreaks of the disease flare as social..
Reuters - Published

Gilead study shows shorter five-day course of remdesivir works as well as 10-day one

Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant..
Reuters - Published

Britain to provide anti-viral drug remdesivir to some COVID-19 patients

Britain will provide the anti-viral drug remdesivir to certain COVID-19 patients that it is most likely to benefit as part of a collaboration with manufacturer Gilead Sciences, the health ministry said..
Reuters - Published

NIH trial: Gilead's drug works best in COVID patients on oxygen

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra..
Reuters - Published

Peer-reviewed data shows Gilead's drug helps COVID-19 recovery time

The U.S. National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences Inc's remdesivir is effective at helping..
Reuters - Published

U.S. doctors call for remdesivir data to guide coronavirus treatment

U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Inc's antiviral drug remdesivir to..
Reuters India - Published Also reported by •Reuters

Remdesivir close to EU's initial authorisation as COVID-19 treatment

The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in..
Reuters India - Published

Part of Gilead's coronavirus drug donation allocated to Japan

Japan has begun treating severely ill COVID-19 patients with Gilead Sciences Inc's coronavirus drug remdesivir, days after granting emergency approval to the medication the company is supplying as part..
Reuters India - Published

Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir

Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus..
Reuters India - Published

Japan says drugmaker Gilead's COVID-19 treatment remdesivir now in use in hospitals

Japan has begun treating severely ill COVID-19 patients with Gilead Sciences Inc's COVID-19 remdesivir drug, a health ministry official said, just days after giving the drug emergency approval as it..
Reuters India - Published

Gilead signs pact with generic drugmakers in India to expand supply of experimental COVID-19 drug remdesivir

Globally, the virus has infected a total of 4.23 million people as of now while the number of deaths has reached 290000.
DNA - Published

Gilead ties up with generic drugmakers for COVID-19 drug supply

Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment..
Reuters India - Published

India's Jubilant signs licensing deal for Gilead's COVID-19 drug

India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries,..
Reuters India - Published

U.S. to allow states to distribute Gilead's remdesivir to fight COVID-19

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United..
Reuters - Published

Exclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers,..
Reuters - Published

Japan approves Gilead Sciences' remdesivir as COVID-19 drug

Japan has approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, the health ministry said on Thursday, making it the country's first officially authorised drug for the disease.
Reuters - Published

Will Gilead price its coronavirus drug for public good or company profit?

Gilead Sciences Inc faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with the novel coronavirus.
Reuters - Published Also reported by •Reuters India

Gilead in talks to expand global supply of COVID-19 drug remdesivir

Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at..
Reuters India - Published

Coronavirus treatment drug remdesivir to arrive in hospitals this week, Gilead CEO says

The CEO of Gilead Sciences says U.S. hospitals should get enough of its drug to fight COVID-19 to treat as many as 200,000 patients this week.
USATODAY.com - Published

Japan aims to fast-track review of anti-viral drug remdesivir

Japan will fast-track a review of Gilead Sciences Inc's antiviral drug remdesivir so that it can hopefully be approved for domestic COVID-19 patients a week after the U.S. firm's filing for such..
Reuters - Published

U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir

Gilead Science Inc's antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in..
Reuters - Published

 Page 1  〉